Cardiff Oncology (CRDF)
(Delayed Data from NSDQ)
$2.68 USD
+0.15 (5.93%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $2.73 +0.05 (1.87%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Brokerage Reports
0 items in cart
Cardiff Oncology, Inc. [CRDF]
Reports for Purchase
Showing records 1 - 20 ( 29 total )
Company: Cardiff Oncology, Inc.
Industry: Medical - Biomedical and Genetics
CRDF-004 Initial Results Expected in 2H24; 2Q24 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Cardiff Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Interim CRDF-004 Results Now Expected in 2H24; 1Q24 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Cardiff Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Confirmatory 2L ONSEMBLE Trial Results; 2023 Financials; Raising PT to $14
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Cardiff Oncology, Inc.
Industry: Medical - Biomedical and Genetics
All Eyes on Initial CRDF-004 Results in Mid-2024; 3Q23 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Cardiff Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Onvansertib Yields Positive Early Pancreatic Cancer Data; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Cardiff Oncology, Inc.
Industry: Medical - Biomedical and Genetics
2Q23 Financial Results Reported; Modulating PT to $12
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Cardiff Oncology, Inc.
Industry: Medical - Biomedical and Genetics
ONSEMBLE Trial Culled in Favor of 1L mCRC Trial in Partnership With Pfizer; Modulating PT to $13
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Cardiff Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cardiff Oncology, Inc.
Industry: Medical - Biomedical and Genetics
First Patient Dosed in Phase 2 ONSEMBLE Trial; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Cardiff Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Multiple Data Readouts in 2023; 2022 Financials; Raising PT to $15
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Cardiff Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cardiff Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Randomized Phase 2 Onvansertib Trial Planned; Encouraging ORR in Avastin-naive mCRC Patients; Modulating PT to $14
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Cardiff Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Key Catalysts Approaching; 2Q22 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Cardiff Oncology, Inc.
Industry: Medical - Biomedical and Genetics
1Q22 Financials Reported; Modulating PT to $22; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Cardiff Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cardiff Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Year-End 2021 Financial Results Reported; Modulating PT to $25
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Cardiff Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Onvansertib Efficacy Maintained in Larger Sample Size; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Cardiff Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Pfizer Invests $15M; 3Q21 Financials Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Cardiff Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cardiff Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Latest Onvansertib Phase 2 Data Encouraging, in our View; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R